Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Viatris, Inc. (VTRS)

Core Viewpoint - A securities class action lawsuit has been filed against Viatris Inc. due to alleged misrepresentation of the impact of a warning letter from the FDA regarding its Indore, India facility, which led to a significant decline in stock price following disappointing financial results [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals or entities that purchased Viatris securities between August 8, 2024, and February 26, 2025 [1]. - The complaint claims that the defendants misrepresented the severity of the FDA's warning letter, downplaying it as a "minor headwind" for the company [2]. - Following the announcement of disappointing fiscal 2025 guidance attributed to the warning letter and import alert, Viatris' stock price fell from $11.24 to$9.53, a decline of approximately 15.21% in one day [2]. Group 2: Investor Information - Investors who acquired shares of Viatris are encouraged to contact the law firm before the lead plaintiff motion deadline on June 3, 2025 [3]. - The lead plaintiff will represent other class members in directing the litigation [3].